Related Experiment Video
Updated: Jun 2, 2026

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs
Published on: December 27, 2016
Facilitation of Ca2+-activated K+ channels (IKCa1) by mibefradil in B lymphocytes
Hae Young Yoo1, Haifeng Zheng, Joo Hyun Nam
1Department of Physiology, Seoul National University College of Medicine, Seoul, South Korea.
Insights
Mibefradil, a T-type calcium channel blocker, activates the calcium-activated potassium channel (IKCa1) in B cells. This selective activation suggests potential therapeutic applications for IKCa1-related cellular responses.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Potassium (K+) channels are crucial for lymphocyte proliferation and activation.
- Mouse B cells express voltage-gated K+ channels (Kv), Ca2+-activated K+ channels (IKCa1), and large-conductance background K+ channels (LK bg).
- Mibefradil, a T-type Ca2+ channel blocker, has shown effects on immune cell proliferation.
Purpose of the Study:
- To investigate the effects of mibefradil on membrane potential and ion channels in murine B cell lines.
- To elucidate the specific ion channel targets of mibefradil in B cells.
Main Methods:
- Whole-cell and inside-out patch clamp electrophysiology on murine B cell lines (WEHI-231, Bal-17) and HEK-293 cells expressing cloned murine IKCa1 (mIKCa1).
- Application of mibefradil and anti-IgM antibody to stimulate B cell receptors (BCR-ligation).
- Use of charybdotoxin, a selective blocker for SK4/IKCa1, to confirm channel involvement.
Main Results:
- Mibefradil inhibited Kv and LK bg currents (IC50s of 1.9 and 2.3 microM, respectively).
- Mibefradil significantly increased IKCa1 current, enhancing Ca2+ sensitivity and maximum activity of mIKCa1.
- Mibefradil induced persistent hyperpolarization in B cells upon BCR-ligation, mediated by IKCa1 activation.
Conclusions:
- This study is the first to report the ion channel-activating effects of mibefradil.
- Mibefradil selectively and potently activates IKCa1.
- Mibefradil-derived drugs may offer therapeutic potential for controlling cellular responses involving IKCa1.
Abstract:
K+ channels play critical roles in the proliferation and activation of lymphocytes. Mouse B cells express large-conductance background K+ channel (LK bg) in addition to the voltage-gated K+ channel (Kv) and Ca2+-activated K+ channel current (IKCa1). Mibefradil, a blocker of T-type Ca2+ channels, has been reported to affect the proliferation of immune cells. In this study, we investigated the effects of mibefradil on the membrane potential and ion channels in murine B cell lines, WEHI-231 and Bal-17. In the whole-cell patch clamp experiments, mibefradil blocked Kv and LK bg current with half inhibitory concentration (IC50), 1.9 and 2.3 microM, respectively. Interestingly, IKCa1 current was increased by mibefradil. In the inside-out patch clamp study with cloned murine IKCa1 (mIKCa1) in HEK-293, mibefradil increased both Ca2+ sensitivity and maximum activity of mIKCa1. At high concentrations (>10 microM), mibefradil inhibited mIKCa1 in a voltage-dependent manner. Application of anti-IgM antibody to stimulate B cell receptors (BCR-ligation) induced transient hyperpolarization of Bal-17 and WEHI-231 cells, which became persistent with 1 microM mibefradil. The hyperpolarizing response was abolished by charybdotoxin, a selective blocker for SK4/IKCa1. In summary, our study firstly reports the ion channel-activating effects of mibefradil. The selective potent activation of IKCa1 suggests that mibefradil-derived drugs might be useful in the control of cell responses related with IKCa1.
Related Concept Videos
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...

